Thyreogen

Thyreogen (also designated Peptide Complex A-2) is an organotropic thyroid bioregulator composed of short peptide fractions — predominantly di-, tri-, and tetrapeptides — with a molecular weight below 5 kDa. The peptides are extracted from the thyroid glands of young bovine and porcine animals through acetic extraction at 3-7°C under controlled pH conditions.

The proposed mechanism, advanced by Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology, holds that these ultrashort peptides cross cellular and nuclear membranes by passive diffusion, a process facilitated by their very low molecular weight. Once in the nucleus, the peptides are hypothesized to bind complementary sequences on DNA promoter regions and interact with histone proteins (H1, H2B, H3, H4), modifying chromatin compaction and thereby modulating gene transcription in a tissue-specific manner.

For thyroid cells specifically, the proposed gene targets include thyroglobulin, thyroid peroxidase, the sodium-iodide symporter, and the TSH receptor — the core machinery of iodine uptake and thyroid hormone synthesis. By acting upstream at the level of gene expression rather than binding surface receptors or supplementing circulating hormones, proponents describe a normalizing or bidirectional effect: upregulating transcription in hypofunctional tissue and theoretically dampening it in overactive tissue.

Important caveats: the precise amino acid sequences present in commercial Thyreogen formulations have not been published in peer-reviewed literature. The epigenetic DNA-binding model is supported by in-vitro work from the Khavinson group but has not been independently reproduced at the level of promoter-binding specificity for thyroid genes.

The clinical evidence for Thyreogen is limited in quantity, geographically concentrated in Russia, and has not been independently replicated outside the originating research group.

The most substantive published human data comes from Gorbachev AL, Lugovaia EA, Ryzhak GA, and Khavinson VKh, in a study titled "Peptide bioregulator efficacy in the correction of reduced thyroid gland function in the residents of Magadan Region," published in Advances in Gerontology (2005, Vol. 16, pp. 80-87; PMID 16075681). The study evaluated Thyramin — the pharmaceutical-grade predecessor to the commercial Thyreogen preparation — in adults and older subjects with hypothyroidism from the Magadan region, where iodine deficiency and climatic stressors compound thyroid disease risk. Outcome measures included TSH levels, thyroid hormone concentrations, and trace element composition in hair samples. The abstract concludes that Thyramin exerts a tissue-specific effect on thyroid gland cells and represents an adequate correction method for reduced thyroid function, but quantitative outcomes and full methodology are available only in Russian.

A small unpublished pilot study conducted at the St. Petersburg Institute (November 2005 - January 2006) enrolled 25 subjects and 19 controls aged 56-67 with primary hypothyroidism. Both groups received standard hypothyroidism treatment; the test group additionally received 1-2 capsules of Thyreogen twice daily for 20 days. The reported outcomes included symptom improvement in approximately 78% of the treated group, with reductions in headache, fatigue, and drowsiness, and thyroid parameters reportedly within physiological norm at 3-5 months follow-up. No adverse effects were documented in this cohort. This study has not been published in a peer-reviewed journal accessible to Western readers.

A morphological study examining ultrasound-assessed structural changes in thyroid tissue among 46 subjects (ages 17-72) with conditions including focal colloid degeneration, adenomatous nodes, chronic thyroiditis, and cysts used a combination of Thymalin, Epithalamin, and Thyramin, with assessment at 4-5 months post-treatment. Full quantitative results were not retrievable in accessible English-language sources.

The broader bioregulator program is described in a 2010 review by Anisimov VN and Khavinson VN in Biogerontology (PMID 19830585; DOI 10.1007/s10522-009-9249-8), which reports that long-term treatment with various peptide preparations increased mean lifespan by 20-40% in rodent models and reduced age-related biomarker changes. No thyroid-specific data are presented in that review. Overall, the evidence base for Thyreogen specifically remains at the case-series and uncontrolled observational level, with no randomized, double-blind, placebo-controlled trials published in indexed Western journals.

Typical dosage: 10 mg (daily for cycles).

Dosage information for Thyreogen is drawn from commercial product labeling and Russian clinical practice recommendations rather than from rigorously designed pharmacokinetic or dose-finding trials.

Standard protocol: • Initial course: 1-2 capsules (each approximately 200 mg total weight, with peptide fraction as the active component) taken twice daily, 15-30 minutes before meals, for 10-30 days. Product labeling often cites a 30-day course (60 capsules) for a first cycle. • Maintenance: 1-2 capsules twice daily for a 10-day course repeated every 3 months (approximately 20 capsules per maintenance cycle). • More frequent cycles: For individuals with significant or persistent thyroid dysfunction, some practitioners report cycles every 1-2 months, though this is not supported by published dose-optimization data.

The St. Petersburg pilot study (2005-2006) used 1-2 capsules twice daily for 20 days as its treatment protocol. The Magadan region study (PMID 16075681) used Thyramin, the pharmaceutical cytamin form, but the exact dosing schedule was not reproduced in the English abstract.

A sublingual (lingual) formulation is also marketed, with the premise that submucosal absorption may avoid first-pass gastrointestinal peptide degradation, though bioavailability comparisons between oral and sublingual routes have not been published for this compound.

No pediatric dosing data exist. No pharmacokinetic data on peak plasma concentration, half-life, or absolute bioavailability have been published for Thyreogen in peer-reviewed literature.

This information is provided for educational and reference purposes only and does not constitute medical advice. Thyroid disorders require diagnosis and management by a qualified physician. Anyone considering Thyreogen should consult their healthcare provider, particularly if they are taking thyroid hormone replacement therapy or have autoimmune thyroid disease.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Combination use of Thyreogen with other Khavinson-class bioregulators or thyroid-supportive agents is reported in Russian clinical practice and the longevity supplement community, but is not supported by controlled combination studies.

• Epitalon (pineal peptide, Ala-Glu-Asp-Gly tetrapeptide): Frequently reported alongside Thyreogen in anti-aging protocols. The rationale is that Epitalon modulates the hypothalamic-pituitary axis and melatonin output, potentially supporting the broader neuroendocrine context in which thyroid regulation operates. Evidence for this pairing is anecdotal.

• Ventfort (vascular bioregulator): Combined on the basis that cardiovascular support may augment thyroid perfusion and systemic hormone delivery. Evidence is anecdotal.

• Thymogen (thymus dipeptide glutamyl-tryptophan): Used in combination in the morphological study (PMID context — Thymalin was the thymus extract equivalent) on the premise that thyroid autoimmune conditions (Hashimoto's thyroiditis) involve immune dysregulation that thymic peptides may modulate. The published ultrasound study used a three-agent combination (Thymalin, Epithalamin, Thyramin), making individual attribution of effect impossible.

• Iodine and L-tyrosine: Some formulations (e.g., Thyroid TIDE PLUS) combine thyroid peptide complexes with iodine, L-tyrosine, selenium, zinc, and vitamin E, supplying the raw biochemical substrates for thyroid hormone synthesis alongside the proposed epigenetic signaling component. The added-value of the peptide fraction over micronutrient supplementation alone has not been tested in a head-to-head study.

All combination approaches noted here are empirical or anecdotal; no controlled trials have evaluated synergistic or additive effects.

Thyreogen is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally safe

Thyreogen has not been evaluated in large-scale formal safety trials. The available safety information derives from small Russian clinical studies, manufacturer documentation, and community reports.

Reported adverse effects: No serious adverse effects were documented in the small St. Petersburg pilot study (n=44) or in the Magadan region study. The Khavinson group's manufacturing FAQ states that cytamin-class peptide bioregulators "produce no side effects" beyond possible individual intolerance to excipients (gelatin shell, microcrystalline cellulose, lactose, calcium stearate).

Potential risks acknowledged in product documentation include: • Allergic or hypersensitivity reactions to capsule excipients (gelatin, lactose, calcium stearate) • Transient shifts in metabolic rate and body temperature during initial use, attributed to adjustment of thyroid function • Possible interactions with thyroid hormone medications (levothyroxine, liothyronine): if Thyreogen were to augment endogenous T4/T3 output, concurrent hormone replacement doses could result in over-replacement; monitoring of TSH is advisable

Contraindications stated by manufacturers: • Pregnancy and lactation (no safety data in these populations) • Status post-total thyroidectomy (no residual thyroid tissue to target, rendering treatment ineffective) • Known hypersensitivity to bovine or porcine glandular preparations

Biological safety considerations: The extraction process (acetic extraction at pH 3.0 at 3-7°C for 6 days) is stated to inactivate microbes and viruses. Immunoblotting testing has been conducted on related cytamin products (Cortexin, Retinalamin) confirming absence of infectious prion proteins, though product-specific prion testing results for Thyreogen have not been published in peer-reviewed literature.

The absence of published serious adverse events must be interpreted with caution given the limited sample sizes and lack of independent safety surveillance. Thyreogen is not approved by the FDA, EMA, or equivalent Western regulatory agency. It is sold as a dietary supplement or natural health product in most jurisdictions.